Scarica l'app Stockscreener
2.45
1.24%
0.03
Dopo l'orario di chiusura:
2.61
0.16
+6.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Alaunos Therapeutics Inc Borsa (TCRT) Ultime notizie
Alaunos Reports Positive Preclinical Metabolic Data for ALN1003 - TipRanks
Alaunos reports preclinical data for obesity drug candidate ALN1003 - Investing.com
Alaunos Therapeutics Reports Positive Preclinical Results for ALN1003 in Addressing Metabolic Disease Markers - Quiver Quantitative
ALN1003 obesity data and cash runway update from Alaunos (NASDAQ: TCRT) - Stock Titan
Alaunos Therapeutics Reports Encouraging Early Obesity Drug Results - Stocktwits
TCRT Q4 2023 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Reports No RevenueGuidance Update - Newser
Alaunos Therapeutics (TCRT) Q4 2023 Earnings Fall Short: EPS $-4.90 Misses MarkBuyback Announcement Report - Newser
Alaunos Therapeutics (TCRT) Reveals Promising Preclinical Data f - GuruFocus
Alaunos Therapeutics, Inc.Common Stock (Nasdaq:TCRT) Stock Quote - FinancialContent
Alaunos Therapeutics Announces Promising Preclinical Results for ALN1003 in Metabolic Syndrome and Obesity Models - Minichart
Alaunos reports preclinical data for obesity drug candidate - Investing.com UK
Alaunos reports preclinical data for obesity drug candidate By Investing.com - Investing.com Nigeria
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models - The Manila Times
Alaunos (Nasdaq: TCRT) shows ALN1003 obesity data, reports $0.354M cash - Stock Titan
Experimental obesity pill shows liver and insulin-resistance effects in mice - Stock Titan
TCRT Alaunos Therapeutics reports widening losses as revenue plummets 50 shares fall 326Social Buy Zones - newser.com
Ziopharm: Q1 Earnings Snapshot - marketscreener.com
Alaunos Therapeutics, Inc. 1Q 2026: Revenue $0K, EPS $(0.59) — 10-Q Summary - TradingView
Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Alaunos Therapeutics (NASDAQ: TCRT) Q1 2026 loss, cash runway and Nasdaq equity deficiency - Stock Titan
TCRT Should I Buy - Intellectia AI
Headline News about Alaunos Therapeutics, Inc.Common Stock - FinancialContent
MSN Money - MSN
TCRT Alaunos Therapeutics reports widening losses as revenue plummets 50%, shares fall 3.26%.Value Pick - newser.com
Alaunos Therapeutics (TCRT) Eps Diluted (TTM) - Zacks Investment Research
TCRT Stock Price, Quote & Chart | ALAUNOS THERAPEUTICS INC (NASDAQ:TCRT) - ChartMill
Why Alaunos Therapeutics (TCRT) looks solid from every angle (Smart Money Flows) 2026-05-06Wall Street Picks - newser.com
Former Alaunos legal chief joins Valion Bio for FDA, CDMO push - Stock Titan
TCRT Alaunos Therapeutics posts wider Q4 2023 loss than analyst estimates, with shares slipping 0.39 percent in today’s trading.Social Trading Insights - newser.com
Alaunos Therapeutics (TCRT) director awarded 6,515 shares at $2.59 - Stock Titan
Alaunos Therapeutics (TCRT) director receives 6,274-share stock grant in lieu of fees - Stock Titan
Director at Alaunos (TCRT) receives 6,032-share stock award - Stock Titan
Alaunos Therapeutics 2025 Proxy Statement – Board Members, Executive Compensation, and Corporate Governance Overview - Minichart
Alaunos Therapeutics (NASDAQ: TCRT) details board, pay and ownership in 10-K/A - Stock Titan
Alaunos Therapeutics (TCRT) Moat Analysis | Q4 2023: EPS Misses EstimatesStability Report - Xã Châu Thành
Alaunos Therapeutics receives Nasdaq notice for non-compliance with equity rule - Investing.com
Alaunos Therapeutics Faces Nasdaq Non-Compliance, Delisting Risk - TipRanks
Alaunos Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Alaunos Therapeutics (NASDAQ: TCRT) faces Nasdaq equity deficiency, delisting risk - Stock Titan
Aug Update: How does Alaunos Therapeutics Inc correlate with Nasdaq2026 Market WrapUp & Long Hold Capital Preservation Plans - baoquankhu1.vn
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):